MeiraGTx Unveils 3-Year Data for Radiation-Induced Xerostomia Gene Therapy
Event summary
- MeiraGTx will present 3-year data from its Phase 1 AQUAx study of AAV-hAQP1 for radiation-induced xerostomia on April 16, 2026.
- Data includes patient-reported outcomes and objective saliva flow measurements for bilateral and unilateral cohorts.
- The open-label trial evaluates the safety and efficacy of AAV-hAQP1 in patients with grade 2/3 xerostomia post-head-and-neck cancer treatment.
- MeiraGTx operates five global manufacturing facilities, including two licensed for GMP viral vector production.
The big picture
MeiraGTx's presentation of 3-year data marks a critical milestone in validating gene therapy for chronic radiation damage. The results could reshape treatment paradigms for head-and-neck cancer survivors, while MeiraGTx's vertically integrated manufacturing model positions it to capitalize on potential commercialization. Success here would reinforce the company's strategy of targeting high-unmet-need conditions with localized genetic medicines.
What we're watching
- Therapeutic Efficacy
- How sustained improvements in xerostomia symptoms will impact AAV-hAQP1's regulatory and commercial prospects.
- Manufacturing Scale
- Whether MeiraGTx can leverage its end-to-end manufacturing capabilities to support potential late-stage development.
- Market Differentiation
- The pace at which long-term data positions AAV-hAQP1 against emerging treatments for radiation-induced xerostomia.
Our editorial coverage:
Related topics